Information Provided By: 
Fly News Breaks for April 17, 2015
ICPT
Apr 17, 2015 | 05:53 EDT
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
